A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC

By sjmartinez • February 25, 2025

Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K. A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC. Future Oncol. 2025 Feb 24:1-13. doi: 10.1080/14796694.2025.2463880. Epub ahead of print. PMID: 39995095.

Tags: Hematology/Oncology, Publications

Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists

Rugo HS, Bardia A, Gradishar WJ, Hamilton EP, Hurvitz SA, Jhaveri K, Mahtani R, Tolaney SM. Expert consensus on treating HR+/HER2- metastatic breast cancer based[...]

Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking Patients

Oh MS, Garon EB, Lisberg AE, Cummings AL, Barrett A, Ashok A, Mauer E, Yilma B, Goldman JW. Brief Report: The Genomic Landscape of Small[...]

Safe Use of Immune Checkpoint Inhibitors in Patients With Autoimmune Disease in a Community Hospital Setting: A Report of Two Cases

Shah VD, Bansil S, Reed JP. Safe Use of Immune Checkpoint Inhibitors in Patients With Autoimmune Disease in a Community Hospital Setting: A Report of[...]